SCHEMBL346581

SCHEMBL346581

OCCN(CCO)c1c[c]ccc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.35
KMT2A Q03164 3/20 0.35
MEN1 O00255 2/20 0.35
HTT P42858 2/20 0.32
GAA P10253 2/20 0.32
PKM P14618 1/20 0.32
MCL1 Q07820 1/20 0.32
KDM4E B2RXH2 2/20 0.32
ATM Q13315 2/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
NPSR1 Q6W5P4 2/20 0.31
LMNA P02545 1/20 0.31
TP53 P04637 1/20 0.31
L3MBTL1 Q9Y468 2/20 0.31
PABPC1 P11940 1/20 0.31
ALDH1A1 P00352 2/20 0.30
NPC1 O15118 1/20 0.30
MITF O75030 1/20 0.30
NSD2 O96028 1/20 0.30
THRB P10828 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14949883 0.89 ALDH1A1 (0.37) MAPTKMT2AMEN1HTTGAA
SCHEMBL131242 0.80 CNR2 (0.31) NPSR1TP53L3MBTL1
SCHEMBL16540335 0.80 EGFR (0.38) MAPTKMT2AMEN1KDM4ESMN1; SMN2
SCHEMBL27948257 0.78 CNR2 (0.31) TP53
SCHEMBL127286 0.77 NR1H2 (0.35) MAPTKMT2AMEN1GAAKDM4E
SCHEMBL1244757 0.76 KCNA5 (0.33) KMT2AMEN1GAAALDH1A1
SCHEMBL1078988 0.76 NPC1 (0.36) MAPTGAAKDM4ENPSR1LMNA
SCHEMBL28219781 0.76 HTR2A (0.34) KDM4ESMN1; SMN2ALDH1A1
SCHEMBL130243 0.75 ALDH1A1 (0.44) MAPTKMT2AMEN1GAAKDM4E
SCHEMBL6199989 0.74 NPC1 (0.39) TP53ALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8889698-B2 Compounds for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2014-11-18 US disclosed
US-20120015905-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015905-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES APOB, HDLBP, FABP3 MAPT 3436/4885KMT2A 3772/4885MEN1 4390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.